Skip to main content
Sudeep Pharma Limited logo

Sudeep Pharma Limited — Investor Relations & Filings

Ticker · SUDEEPPHRM ISIN · INE0QPI01025 LEI · 335800ESH1W57DIPAN45 BSE.NS Manufacturing
Open in API
Filings indexed 75 across all filing types
Latest filing 2026-02-07 Investor Presentation
Country IN India
Listing BSE.NS SUDEEPPHRM

About Sudeep Pharma Limited

https://www.sudeeppharma.com/

Sudeep Pharma Limited specializes in the manufacturing of mineral-based excipients and active pharmaceutical ingredients (APIs). The company’s core portfolio includes high-purity mineral salts such as Calcium Phosphates, Calcium Carbonate, and Calcium Sulfate, which are utilized as essential components in solid dosage formulations and nutritional supplements. These products function as diluents, binders, and mineral sources across various applications. The organization maintains advanced production facilities compliant with international quality standards, including GMP, USP, EP, and BP. A strategic partnership with JRS Pharma enhances its technical expertise and global supply chain capabilities. Sudeep Pharma focuses on providing high-quality, regulatory-compliant mineral solutions to meet the demands of global markets, emphasizing research, development, and stringent quality control processes.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 of SEBI (LODR), we hereby submit Investor Presentation for the unaudited financials as on third quarter and nine months ended on 31st December 2025
Investor Presentation Classification · 95% confidence The document is dated February 7, 2026, and is addressed to stock exchanges referencing Regulation 30 of SEBI (LODR) Regulations, which governs disclosures related to financial results and presentations. The subject line clearly states "Q3FY26 - Result Presentation." The content includes detailed financial performance highlights for the third quarter and nine months ended December 31, 2025, including revenue, EBITDA, PAT, segmental and geographical breakups, and strategic updates. It also contains a message from the Managing Director and detailed operational and strategic information. The document is titled "Investor Presentation" and includes forward-looking statements and safe harbor disclaimers typical of investor presentations. It is not a full annual or quarterly report but a presentation summarizing quarterly results and company strategy for investors. Therefore, the document fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed financial data support this classification with high confidence.
2026-02-07 English
Intimation for Re-schedule of Earnings Call with Analysts/Investors on 09th February 2026 at 11:00 a.m. all the investors are requested to take note of the same.
Call Transcript Classification · 90% confidence The document is a notification about the rescheduling of an earnings call with analysts and investors to discuss the company's quarterly financial results for the quarter and nine months ended December 31, 2025. It references Regulation 30 of the SEBI Listing Regulations, which governs disclosures related to corporate events. The document includes details about the date, time, and access information for the call but does not contain any financial data or results itself. It is an announcement related to the earnings call, not the earnings release or the transcript of the call. Given the document length is short (3130 characters) and it is primarily an announcement of the earnings call event, the appropriate classification is Call Transcript (CT) because it is about the call event, but since it is only a notice of rescheduling and invitation, it is more accurately a Regulatory Filing (RNS) as it does not contain the transcript or the earnings release itself. However, since the document is specifically about the earnings call scheduling, the best fit is Call Transcript (CT) category as it relates directly to the earnings call event. Confidence is high due to clear references to earnings call scheduling and no financial data present.
2026-02-07 English
Pursuant to Regulation 30 and 47 of SEBI (LODR) please find attached newspaper publication for extract of un-audited financial results for the third quarter and nine months ended 31st December 2025.
Regulatory Filings
2026-02-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 70% confidence The document is a notification about the rescheduling of an earnings call with analysts and investors to discuss the company's quarterly financial results for the quarter and nine months ended December 31, 2025. It references Regulation 30 of the SEBI Listing Regulations, which governs disclosures related to events such as earnings calls. The document includes details about the date, time, and access information for the call but does not contain any financial data or results itself. It is an announcement related to the earnings call, not the earnings release or transcript itself. Therefore, the document is best classified as a Call Transcript (CT) announcement or related to the earnings call event. However, since it is only a rescheduling notice and invitation, it is not the transcript itself but an announcement about the call. Given the options, the closest and most appropriate classification is Call Transcript (CT) as it pertains directly to the earnings call event, with moderate confidence due to the nature of the document being a scheduling notice rather than the transcript itself.
2026-02-07 English
Copy of Newspaper Publication
Regulatory Filings
2026-02-07 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is dated 6th February 2026 and is addressed to stock exchanges referencing Regulation 30(6) of SEBI Listing Regulations, indicating a regulatory compliance announcement. It reports the outcome of a Board Meeting held on the same date, including the appointment of an internal auditor and approval of unaudited standalone and consolidated financial results for the third quarter and nine months ended 31 December 2025. The document includes a Limited Review Report by the statutory auditors on the unaudited financial results, prepared under Indian Accounting Standard 34 for interim financial reporting. The financial results contain detailed income statement data for the quarter and year-to-date periods. The presence of unaudited financial results for a quarter and nine months, along with a limited review report, aligns with an Interim / Quarterly Report. The document is substantive and contains actual financial data and analysis, not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2026-02-06 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.